Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Scholte, Martijn ^a   Timmers, Leo ^b   Bernink, Flip J P ^a   Denham, Robert N ^a   Beek, Aernout M ^a   Kamp, Otto ^a   Diamant, Michaela ^a   Horrevoets, Anton J G ^a   Niessen, Hans W M ^a   Chen, Weena J Y ^a   van Rossum, Albert C ^a   van Royen, Niels ^a   Doevendans, Pieter A ^b   Appelman, Yolande ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Exenatide; Glucagon like peptide 1; Myocardial infarction; Reperfusion injury

Indexed keywords

EXENDIN 4; PLACEBO; PEPTIDE; VENOM;

ACUTE HEART INFARCTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; TREATMENT OUTCOME; ACUTE DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEART INFARCTION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ACUTE DISEASE; CLINICAL PROTOCOLS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PROSPECTIVE STUDIES; VENOMS;

EID: 80455158258     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-240     Document Type: Article

References (23)

1. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol 2004, 44:1533-1542. 10.1016/j.jacc.2004.06.071, 15489082.
2. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002, 39:30-36.
3. O'Neill W, Timmis GC, Bourdillon PD, Lai P, Ganghadarhan V, Walton J, Ramos R, Laufer N, Gordon S, Schork MA, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986, 314:812-818. 10.1056/NEJM198603273141303, 2936956.
4. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004, 61:414-426. 10.1016/j.cardiores.2003.12.023, 14962473.
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135. 10.1056/NEJMra071667, 17855673.
6. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997, 96:1152-1156.
7. van der Horst IC, Zijlstra F, van 't Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, Bilo HJ. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003, 42:784-791. 10.1016/S0735-1097(03)00830-1, 12957421.
8. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57-65. 10.1016/0735-1097(95)00126-K, 7797776.
9. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998, 98:2227-2234.
10. Ceremuzynski L, Budaj A, Czepiel A, Burzykowski T, Achremczyk P, Smielak-Korombel W, Maciejewicz J, Dziubinska J, Nartowicz E, Kawka-Urbanek T, et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999, 13:191-200. 10.1023/A:1007787924085, 10439881.
11. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Jama 2005, 293:437-446.
12. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
13. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995, 358:219-224. 10.1016/0014-5793(94)01430-9, 7843404.
14. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001, 89:445-452. 10.1161/hh1701.095716, 11532906.
15. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151. 10.2337/diabetes.54.1.146, 15616022.
16. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
17. Davidson MB, Bate G, Kirkpatrick P. Exenatide. Nat Rev Drug Discov 2005, 4:713-714. 10.1038/nrd1828, 16178120.
18. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510. 10.1016/j.jacc.2008.10.033, 19195607.
19. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249. 10.1016/j.regpep.2007.10.001, 17976835.
20. King AB, Wolfe G, Healy S. Clinical observations of exenatide treatment. Diabetes Care 2006, 29:1984.
21. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF, Arai AE. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 2006, 113:1865-1870. 10.1161/CIRCULATIONAHA.105.576025, 16606793.
22. Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging 2009, 2:569-576. 10.1016/j.jcmg.2008.11.018, 19442942.
23. Wright J, Adriaenssens T, Dymarkowski S, Desmet W, Bogaert J. Quantification of myocardial area at risk with T2-weighted CMR: comparison with contrast-enhanced CMR and coronary angiography. JACC Cardiovasc Imaging 2009, 2:825-831. 10.1016/j.jcmg.2009.02.011, 19608131.